Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States

Journal of Addictive Diseases

Volumn 32, Issue 1, 2013, Pages 26-38

  Sembower, Mark A ^a   Ertischek, Michelle D ^a   Buchholtz, Chloe ^b   Dasgupta, Nabarun ^c   Schnoll, Sidney H ^a  

^a PINNEY ASSOCIATES   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

amphetamine; Attention deficit hyperactivity disorder; methylphenidate; psycho stimulants; substance abuse and dependence

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; HUMAN; POISON CENTER; POSTMARKETING SURVEILLANCE; PRESCRIPTION; UNITED STATES;

ADOLESCENT; ADULT; AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; DRUG AND NARCOTIC CONTROL; DRUG PRESCRIPTIONS; HUMANS; METHYLPHENIDATE; PHARMACIES; PHYSICIAN'S PRACTICE PATTERNS; POISON CONTROL CENTERS; PRESCRIPTION DRUG MISUSE; UNITED STATES;

EID: 84875316350     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2012.759880     Document Type: Article

References (22)

1. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attentiondeficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004; 14:11-28. (Pubitemid 37495027)
2. Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict 2007; 16(Suppl 1):35-42.
3. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addictionrelated surveillance (RADARS). Pain Med 2007; 8:157-70.
4. Inciardi JA, Surratt HL, Lugo Y, Cicero TJ. The diversion of prescription opioid analgesics. Law Enforc Exec Forum 2007; 7:127-141.
5. American Association of Poison Control Centers. AAPCC National Poison Data System (NPDS). Reference Manual. Washington, DC: American Association of Poison Control Centers; 2007.
6. IMS Health. National Prescription Audit (NPA) Basic Data Report, Q2 2011. Plymouth Meeting, PA: IMS Health Incorporated; 2011.
7. Inciardi JA, Cicero TJ, Munoz A, et al. The diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis 2006; 25:53-8. (Pubitemid 44157069)
8. Watson WA, Litovitz TL, Belson MG, et al. The Toxic Exposure Surveillance System (TESS): risk assessment and real-time toxicovigilance across United States poison centers. Toxicol Appl Pharmacol 2005; 207:604-10.
9. Bailey JE, Barton PL, Lezotte D, Lowenstein SR, Dart RC. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug Alcohol Depend 2006; 84:182-7. (Pubitemid 44137460)
10. Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clin Toxicol (Phila) 2007; 45:144-51. (Pubitemid 46280021)
11. SmithMY, Dart R, Hughes A, et al. Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids. Am J Drug Alcohol Abuse 2006; 32:465-78. (Pubitemid 44231570)
12. Dasgupta N, Bailey EJ, Cicero T, et al. Postmarketing surveillance of methadone and buprenorphine in the United States. Pain Med 2010; 11:1078-91.
13. Smith MY, Schneider MF, Wentz A, Hughes A, Haddox JD, Dart R. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches. Clin Toxicol (Phila) 2007; 45:23-30.
14. Forrester MB. Methylphenidate abuse in Texas, 1998-2004. J Toxicol Environ Health A 2006; 69:1145-53.
15. Forrester MB. Adderall abuse in Texas, 1998-2004. J Toxicol Environ Health A 2007; 70:658-64. (Pubitemid 46328455)
16. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007; 2:32.
17. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45:408-14. (Pubitemid 43675545)
18. Centers for Disease Control and Prevention. Increasing prevalence of parentreported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. Morbidity and Mortality Weekly Report 2010; 59:1439-43.
19. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163:716-23. (Pubitemid 44464584)
20. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sørensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9:199-205.
21. LoVecchio F, Katz K, Watts D, Pitera A. Media influence on Poison Center call volume after 11 September 2001. Prehosp Disaster Med 2004; 19:185.
22. Krenzelok EP, Mrvos R. Initial impact of toll-free access on poison center call volume. Vet Hum Toxicol 2003; 45:325-7. (Pubitemid 37523544)